Key patent now granted in major markets including the U.S., Europe, Canada & South Korea
Patent claims cover use of the Company's lead product candidate, Quilience® (mazindol ER) in both attention deficit hyperactivity disorder (ADHD) & narcolepsy
Tuesday, January 4, 2022
NLS Pharma Gets US Patent for ADHD Med Extended-Release Formulation
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.